A detailed history of Citigroup Inc transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Citigroup Inc holds 220,543 shares of PCVX stock, worth $19.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
220,543
Previous 165,795 33.02%
Holding current value
$19.1 Million
Previous $12.5 Million 101.13%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$70.52 - $117.12 $3.86 Million - $6.41 Million
54,748 Added 33.02%
220,543 $25.2 Million
Q2 2024

Aug 12, 2024

BUY
$60.06 - $78.77 $1.26 Million - $1.65 Million
20,928 Added 14.45%
165,795 $12.5 Million
Q1 2024

May 10, 2024

BUY
$59.79 - $81.05 $3.94 Million - $5.35 Million
65,955 Added 83.58%
144,867 $9.9 Million
Q4 2023

Feb 09, 2024

SELL
$45.35 - $63.41 $749,499 - $1.05 Million
-16,527 Reduced 17.32%
78,912 $4.96 Million
Q3 2023

Nov 09, 2023

BUY
$46.0 - $53.1 $773,536 - $892,929
16,816 Added 21.39%
95,439 $4.87 Million
Q2 2023

Aug 10, 2023

SELL
$34.66 - $54.07 $2.41 Million - $3.76 Million
-69,463 Reduced 46.91%
78,623 $3.93 Million
Q1 2023

May 11, 2023

BUY
$36.27 - $47.2 $1.06 Million - $1.38 Million
29,320 Added 24.69%
148,086 $5.55 Million
Q4 2022

Feb 09, 2023

SELL
$20.58 - $47.95 $754,730 - $1.76 Million
-36,673 Reduced 23.59%
118,766 $5.69 Million
Q3 2022

Nov 10, 2022

BUY
$21.69 - $28.53 $2.16 Million - $2.84 Million
99,373 Added 177.24%
155,439 $3.73 Million
Q2 2022

Aug 10, 2022

BUY
$17.68 - $26.58 $772,368 - $1.16 Million
43,686 Added 352.88%
56,066 $1.22 Million
Q1 2022

May 12, 2022

SELL
$17.46 - $26.36 $594,565 - $897,637
-34,053 Reduced 73.34%
12,380 $299,000
Q4 2021

Feb 10, 2022

BUY
$19.32 - $26.45 $408,791 - $559,655
21,159 Added 83.72%
46,433 $1.11 Million
Q3 2021

Nov 10, 2021

BUY
$20.26 - $26.97 $512,051 - $681,639
25,274 New
25,274 $641,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.13B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.